J&J Aims For Virology Leadership, But Pipeline Covers Traditional Strengths
Executive Summary
Johnson & Johnson is positioning itself to become a major player in the virology market through its recently approved protease inhibitor Prezista and the development of two non-nucleoside reverse transcriptase inhibitors
You may also be interested in...
J&J Projects Nine NME Filings By 2010, Keeping Pace With Previous Years
With the Jan. 22 filing of the pain medication tapentadol, Johnson & Johnson made the first of the nine new molecular entity filings it expects to make through 2010
J&J Projects Nine NME Filings By 2010, Keeping Pace With Previous Years
With the Jan. 22 filing of the pain medication tapentadol, Johnson & Johnson made the first of the nine new molecular entity filings it expects to make through 2010
J&J Growth Plan Calls For Four Virology Filings In As Many Years
Johnson & Johnson's next generation non-nucleoside reverse transcriptase inhibitor TMC 125 is on deck to be the first of the firm's four virology NDAs over the next four years, Group Chairman Julie McHugh said during an analyst update outlining the company's growth strategy in New Brunswick, N.J. June 7